2021
Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma
Zhu G, Su H, Johnson CH, Khan SA, Kluger H, Lu L. Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma. European Journal Of Cancer 2021, 151: 25-34. PMID: 33962358, PMCID: PMC8184628, DOI: 10.1016/j.ejca.2021.03.053.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBacteriaBacterial LoadBacterial TranslocationChemokinesClostridialesCytotoxicity, ImmunologicFemaleGastrointestinal MicrobiomeHumansLymphocyte CountLymphocytes, Tumor-InfiltratingMaleMelanomaMiddle AgedPrognosisSkin NeoplasmsT-Lymphocytes, CytotoxicTumor MicroenvironmentYoung AdultConceptsT cellsCutaneous melanomaPatient survivalGut microbiomeAdjusted hazard ratioT cell infiltrationChemokine gene expressionChemokine levelsCytotoxic CD8Hazard ratioSystemic inflammationShorter survivalCCL5 expressionPatient outcomesCD8Immune responseMortality riskGut microbiotaSurvival analysisMelanomaTumor nicheHuman cancersSurvivalSignificant correlationPositive associationInterplay between RNA Methylation Eraser FTO and Writer METTL3 in Renal Clear Cell Carcinoma Patient Survival
Zhao J, Lu L. Interplay between RNA Methylation Eraser FTO and Writer METTL3 in Renal Clear Cell Carcinoma Patient Survival. Recent Patents On Anti-Cancer Drug Discovery 2021, 16: 363-376. PMID: 33563180, DOI: 10.2174/1574892816666210204125155.Peer-Reviewed Original ResearchConceptsMETTL3 mRNASurvival analysisFTO mRNAKaplan-Meier survival curvesAdjusted hazard ratioMultivariate Cox regressionRenal clear cell carcinomaClear cell carcinomaInflammation-related genesPotential prognostic markerM6A methyltransferase METTL3Upregulation of FTOHazard ratioCox regressionPatient survivalPrognostic valueCell carcinomaPrognostic markerSuperior survivalImmune responseMETTL3 expressionDifferential expressionClinical relevanceLower DNA methylationSurvival curves
2020
Syndecan-1 and KRAS Gene Expression Signature Associates With Patient Survival in Pancreatic Cancer.
Wu Y, Huang H, Fervers B, Lu L. Syndecan-1 and KRAS Gene Expression Signature Associates With Patient Survival in Pancreatic Cancer. Pancreas 2020, 49: 1187-1194. PMID: 32898003, DOI: 10.1097/mpa.0000000000001654.Peer-Reviewed Original ResearchConceptsSyndecan-1Patient survivalPancreatic cancerAdjusted hazard ratioPancreatic cancer patientsKRAS somatic mutationsSDC1 mRNASomatic mutationsHazard ratioCancer patientsClinical dataSurvival analysisKRASPatientsKyoto EncyclopediaKRAS mRNAElevated mortalityGenomes (KEGG) pathway analysisCancerPathway analysisLower methylationMolecular characteristicsSurvivalMRNANegative correlation
2019
MicroRNA-34a suppresses aggressiveness of hepatocellular carcinoma by modulating E2F1, E2F3, and Caspase-3
Han R, Chen X, Li Y, Zhang S, Li R, Lu L. MicroRNA-34a suppresses aggressiveness of hepatocellular carcinoma by modulating E2F1, E2F3, and Caspase-3. Cancer Management And Research 2019, 11: 2963-2976. PMID: 31114344, PMCID: PMC6489561, DOI: 10.2147/cmar.s202664.Peer-Reviewed Original ResearchPrimary hepatocellular carcinomaHepatocellular carcinomaKaplan-Meier survival curvesNormal tissuesSNU-449Cell proliferationLiver cancer cellsQuantitative reverse transcription PCROverall survivalPatient survivalCaspase-3 activityHCC patientsReverse transcription-PCRAntineoplastic roleBetter survivalTreatment groupsTumor aggressivenessRT-qPCR resultsSurvival analysisSurvival curvesMeta-AnalysisCASP3 activityMicroRNA-34aCancer cellsCell invasion
2017
Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival
Yang JC, Risch E, Zhang M, Huang C, Huang H, Lu L. Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival. Future Oncology 2017, 13: 1981-1990. PMID: 28829218, DOI: 10.2217/fon-2017-0084.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdenocarcinoma, MucinousAdultAgedAged, 80 and overBiomarkers, TumorCystadenocarcinoma, SerousEndometrial NeoplasmsFemaleFollow-Up StudiesHumansInsulin-Like Growth Factor IIMethyltransferasesMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsPrognosisSurvival RateConceptsOvarian cancer survivalIGF-IICancer survivalOvarian cancerDisease progression-free survivalMultivariate Cox regression modelProgression-free survivalRisk of deathCox regression modelIGF-II expressionClinical followSurvival analysisClinical implicationsIGFNormal tissuesHeterogeneous outcomesSurvivalCancerMolecular signaturesAssociationRegression modelsRNA sequencingSupNSUN2Relapse
2016
LIN-28B/let-7a/IGF-II axis molecular subtypes are associated with epithelial ovarian cancer prognosis
Lu L, Katsaros D, Canuto EM, Biglia N, Risch HA, Yu H. LIN-28B/let-7a/IGF-II axis molecular subtypes are associated with epithelial ovarian cancer prognosis. Gynecologic Oncology 2016, 141: 121-127. PMID: 26751131, DOI: 10.1016/j.ygyno.2015.12.035.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancer prognosisOvarian cancer prognosisMolecular subtypesCancer prognosisSurvival analysisMultivariate Cox regression modelKaplan-Meier survival curvesEpithelial ovarian cancer tissuesCox regression modelEpithelial ovarian cancerReduced relapse riskOvarian cancer tissuesIGF-II mRNAQuantitative reverse transcription PCRRelapse riskReverse transcription-PCROvarian cancerBetter survivalCancer tissuesLin-28BSurvival curvesClinical implicationsIGFPrognosisSubtypes
2015
Circulating tumor cell clusters-associated gene plakoglobin and breast cancer survival
Lu L, Zeng H, Gu X, Ma W. Circulating tumor cell clusters-associated gene plakoglobin and breast cancer survival. Breast Cancer Research And Treatment 2015, 151: 491-500. PMID: 25957595, DOI: 10.1007/s10549-015-3416-1.Peer-Reviewed Original ResearchConceptsBreast cancer survivalCancer survivalBreast cancerTumor cellsDisease-specific deathBreast cancer recurrencePotential prognostic biomarkerBreast cancer metastasisEpithelial-mesenchymal transitionHigh metastatic potentialFurther metastasesPatient survivalCancer recurrencePrognostic biomarkerTherapeutic targetSurvival analysisMetastatic potentialCancer metastasisMajor causeHigh expressionEpithelial cellsCancerRole of plakoglobinDouble-edged functionSurvival
2011
MicroRNA let-7a: A potential marker for selection of paclitaxel in ovarian cancer management
Lu L, Schwartz P, Scarampi L, Rutherford T, Canuto EM, Yu H, Katsaros D. MicroRNA let-7a: A potential marker for selection of paclitaxel in ovarian cancer management. Gynecologic Oncology 2011, 122: 366-371. PMID: 21571355, DOI: 10.1016/j.ygyno.2011.04.033.Peer-Reviewed Original ResearchConceptsLow let-7aDisease progressionLet-7aSurvival analysisEpithelial ovarian cancer patientsPlatinum-based chemotherapyOvarian cancer managementOvarian cancer patientsAddition of paclitaxelType of treatmentLet-7a expressionOvarian cancer resistanceOverall survivalDifferent chemotherapyEOC patientsPatient survivalSurvival outcomesDisease stageOvarian tumorsCancer patientsTumor gradeDisease outcomeCancer managementBetter survivalEOC survival